Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.48 |
| ▸ | PDE4A | P27815 | 1/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.48 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 6/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9177025 | 1.00 | PTPN1 (0.50) | PTPN1PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL5619991 | 0.90 | MAPT (0.50) | PTPN1MEN1KMT2AMAPTLMNA | |
| SCHEMBL5619986 | 0.90 | MAPT (0.50) | PTPN1MEN1KMT2AMAPTLMNA | |
| SCHEMBL9177615 | 0.89 | PDE4B (0.46) | PTPN1PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL25195154 | 0.87 | PDE4B (0.45) | PTPN1PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL30384030 | 0.87 | PDE4B (0.45) | PTPN1PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL11959784 | 0.86 | ABCG2 (0.63) | PTPN1PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL25192649 | 0.86 | CYP3A4 (0.54) | PTPN1MEN1KMT2AMAPTLMNA | |
| SCHEMBL31233307 | 0.86 | MAOB (0.53) | PTPN1TNFRSF1AMEN1KMT2AMAPT | |
| SCHEMBL5619965 | 0.86 | MAOB (0.53) | PTPN1TNFRSF1AMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | YewSavin, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| EP-4429763-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | Yewsavin, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023086388-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-9139672-B2 | Polymerizable compound, liquid crystal composition, and liquid crystal display device | JNC CORPORATION (JP) | 2015-09-22 | — | — | US | disclosed |
| US-9139672-B2 | Polymerizable compound, liquid crystal composition, and liquid crystal display device | JNC CORPORATION (JP) | 2015-09-22 | — | — | US | disclosed |
| US-20140346399-A1 | POLYMERIZABLE COMPOUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2014-11-27 | — | — | US | disclosed |
| US-20140346399-A1 | POLYMERIZABLE COMPOUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2014-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | PTPN1 1308/4885PDE4B 2645/4885PDE4A 3506/4885 |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | SERPINC1, SERPINE1, SERPINH1 | PTPN1 1520/4885PDE4B 3192/4885PDE4A 3576/4885 |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | SERPINC1, SERPINE1, SERPINH1 | PTPN1 1520/4885PDE4B 3192/4885PDE4A 3576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.